Author: toxlaw

A large blood–vitreous ethanol discrepancy should prompt investigation of the specimens and circumstances before either result is converted into an earlier blood alcohol concentration. Brunet and Mura described one case with blood ethanol of 2.8 g/L and vitreous ethanol of 0.3 g/L. Only after obtaining more information did the laboratory learn that the death involved a firearm.

What was actually reported?

The laboratory initially received blood and vitreous humor without further case information. Headspace gas chromatography with flame-ionization detection produced the two ethanol measurements. The case account did not specify the blood collection vessel, the exact wound path, the death-to-collection interval, or the specimens’ complete preservation and storage history.

Those omissions limit reconstruction. The blood value cannot be relabeled femoral blood, and the case does not document a precisely timed change in ethanol concentration after death. Both results described the collected material at analysis.

Why the additional history mattered

The authors discussed gastric rupture and mixing of alcohol-rich gastric contents with blood as a possible explanation for discordant findings, particularly in deaths involving traumatic injury. Such contamination would be different from redistribution of absorbed ethanol between otherwise intact biological compartments.

However, the short case description did not report a demonstrated gastric rupture, measured gastric ethanol, cytological proof of contamination, or a quantified contamination fraction. The explanation should remain a case-context hypothesis rather than an experimentally established mechanism in this individual.

A separate blind-stick collection report with cytological evidence of gastric contamination illustrates the kind of additional evidence that can substantiate a specimen-source concern. That evidence cannot be imported into this gunshot case.

The paired series did not supply an individual correction

In the same paper, the authors reported 107 blood–vitreous pairs analyzed during 2009–2010. Seventy-five were negative in both matrices. Among the other 32, the mean vitreous/blood ratio was 1.15 with a standard deviation of 0.41.

That variability matters. The positive-pair average did not describe all 107 cases, and an average ratio was not a rule that every person’s vitreous must exceed blood. The gunshot example’s very different pattern cannot be corrected simply by applying that mean.

Nor should the average from this series be treated as a validated estimate of the concentration during life. The laboratory observations did not provide an independent prediction study establishing a guaranteed error interval for a new, potentially compromised specimen.

What the vitreous result added

The 0.3 g/L vitreous measurement supplied a second compartment that challenged an uncomplicated reading of 2.8 g/L blood. It was useful precisely because the discrepancy could reveal that the specimens required different interpretation.

It did not independently establish a particular earlier blood concentration, exclude every postmortem change, or determine impairment. A lower vitreous result is not a universal certificate that another specimen is contaminated.

What to retain in a case review

Preserve both measured values and their units, collection records, wound and autopsy findings, any gastric-content results, and the laboratory method. The report does not give numerical detection limits, quantitation limits or precision for this ethanol workflow; those must not be invented.

The lesson is to use a disagreement to investigate provenance. It does not justify selecting whichever number favors a conclusion or treating one concentration as a stand-alone cause-of-death finding.

Primary source

Brunet B, Mura P. L’humeur vitrée en toxicologie médico-légale : revue de la littérature et applications [Vitreous humor as an alternative matrix in forensic toxicology: literature review and applications]. Annales de Toxicologie Analytique. 2012;24(1):9–15. doi:10.1051/ata/2012004. The case findings discussed here are the authors’ own laboratory observations within this review-and-applications paper.

A compound can be associated with higher spontaneous movement in one comparison and less amphetamine-related movement in another. That finding is not necessarily contradictory. A 2008 rat experiment with the neurotensin-1 receptor agonist PD149163 shows why the treatment history, comparator and type of movement must accompany the result.

The study investigated a preclinical behavioral response relevant to developing possible antipsychotic drugs. It did not test treatment of psychosis in people or determine whether a person with amphetamine in blood was impaired.

What did the four groups receive?

Feifel and colleagues used thirty-two male Sprague-Dawley rats, divided into four groups of eight after matching on initial locomotor activity. One group received 1 mg/kg PD149163 subcutaneously each day for eight days. The remaining twenty-four rats received saline during that pretreatment period.

On day nine, the saline-pretreated rats were divided among saline followed by saline, saline followed by 0.5 mg/kg amphetamine, and PD149163 followed by amphetamine. The repeatedly PD149163-treated group received its ninth PD149163 injection followed by amphetamine.

The first and second day-nine injections were separated by twenty minutes. Both drugs were administered subcutaneously. The PD149163 dose was 1 mg/kg; the amphetamine dose was 0.5 mg/kg. These are administered animal doses, not blood concentrations or proposed human doses.

How was movement counted?

Infrared beam arrays surrounded the testing cages. Consecutive interruptions of different adjacent beams were counted as ambulation, helping distinguish movement through the cage from repeated activity at approximately the same location.

The investigators separately examined beam interruptions not followed by an adjacent-beam interruption. They treated that measure as preferentially sensitive to stereotyped movements. Neither measure is a complete description of behavior, and an automated beam category should not be translated directly into a human psychiatric symptom.

The main analysis window lasted thirty minutes, beginning ten minutes after drug administration. An effect in that window is not automatically evidence of what happened throughout the day.

What happened before the amphetamine challenge?

Across the first eight treatment days, there was a significant interaction between treatment and day, even though neither the overall day effect nor the overall treatment effect was significant. The repeatedly PD149163-treated animals tended to move less initially but showed more ambulation than saline animals by day eight.

At that day-eight comparison, the eight PD149163-treated rats were compared with the pooled twenty-four saline-treated rats. The difference was statistically significant. The finding describes a changing pattern over days, rather than an unqualified statement that PD149163 always suppressed or always stimulated movement.

Could familiarity with the cage explain the difference?

The authors considered whether PD149163 merely prevented normal habituation to the testing environment. They examined the twenty-minute period before each day’s injection. Across that predose period, activity fell from day one to day eight in both groups: 58.3% with saline and 65.3% with PD149163.

That comparison argued against a simple failure to become familiar with the cage. It did not directly identify the molecular mechanism behind the postinjection movement pattern. Proposed changes in dopamine signaling remained explanations to investigate, rather than measurements completed by this experiment.

Did repeated PD149163 still reduce amphetamine-related movement?

On day nine, amphetamine after saline increased ambulation relative to saline alone. Animals receiving PD149163 with amphetamine had less ambulation than the saline/amphetamine group, whether PD149163 was being given for the first time or after eight previous daily doses.

The acute and repeated PD149163 groups did not significantly differ from each other on ambulation. The authors interpreted this as persistence of the anti-hyperlocomotion effect without demonstrated tolerance under their regimen. However, a nonsignificant difference between groups of eight is not a formal demonstration of equivalence or proof that no smaller tolerance effect existed.

The pretreatment drug was PD149163. The rats did not receive eight days of amphetamine before this challenge. Describing the experiment as showing absence of tolerance to repeated amphetamine would misidentify the exposure being tested.

Did every movement measure improve?

No. Amphetamine also increased the nonambulatory beam-interruption measure. Both acute and repeated PD149163 groups had numerically lower counts than the saline/amphetamine group, but neither reduction reached statistical significance.

That null finding matters. The paper supported an effect on the measured ambulation outcome, not statistically established normalization of every movement category. Separating the categories also helped address whether lower ambulation simply reflected greater stereotyped movement, but did not replace direct assessment of all possible motor effects.

What did the design leave unresolved?

The day-nine experiment did not contain a PD149163-plus-saline group without amphetamine, so it was not a complete factorial comparison of every treatment combination on that testing day. The earlier spontaneous-movement observations provide context but should not be mistaken for that missing simultaneous control.

The authors also discussed apparently conflicting findings from other dosing schedules, including continuous central infusion. Their experiment did not directly compare those schedules or prove that receptor selectivity alone explained the differences.

The useful conclusion is specific: under this once-daily peripheral regimen, the compound’s changing effect on spontaneous movement did not preclude a persisting reduction of amphetamine-related ambulation. That is a controlled animal finding about selected endpoints. It is not clinical proof of antipsychotic efficacy, a validated treatment recommendation, or a basis for inferring an individual’s functioning from drug presence.

References

Feifel D, Melendez G, Murray RJ, et al. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology. 2008;200(2):197–203. doi:10.1007/s00213-008-1197-5. Historical primary research in thirty-two male rats.

A mathematical model can link plasma drug concentrations with a measured brain response without turning a plasma result into a direct measurement of that response. A 2019 study by van Gaalen and colleagues illustrates both the scientific value and the limits of that approach for dextroamphetamine.

The investigators developed a pharmacokinetic–pharmacodynamic model, commonly shortened to PK–PD. Pharmacokinetics described the drug’s distribution and elimination; pharmacodynamics described the changing dopamine response. The model integrated animal experiments and earlier published datasets. It was not a human impairment calculator.

What was measured, and in which specimens?

The new experiments used a single intravenous bolus of 0.1 mg/kg dextroamphetamine, expressed as free base, in male rats and male cynomolgus monkeys. The investigators measured dextroamphetamine in plasma, brain extracellular fluid and cerebrospinal fluid. They also measured dopamine in brain extracellular fluid using microdialysis.

These matrices have different meanings. Plasma is the liquid fraction obtained after centrifuging anticoagulated blood. Extracellular fluid is fluid outside brain cells sampled locally through a probe. Cerebrospinal fluid is another compartment, not a sample of every brain synapse. Dopamine was the response analyte; dextroamphetamine was the administered drug.

Keeping those distinctions intact prevents a common interpretive shortcut: calling all the results either a blood level or a brain level. A whole-blood forensic result is also not automatically the same quantity as the unbound plasma concentration used in the model.

How many animals supplied the new data?

Eleven Wistar rats contributed to the new low-dose experiments. All supplied blood samples, but the matrix-specific datasets were smaller: four rats supplied extracellular-fluid drug data and five supplied cerebrospinal-fluid drug data, with overlap between these groups. A separate group of five supplied extracellular dopamine data.

Three cynomolgus monkeys contributed overall, but that number does not describe three independent animals for every endpoint. Extracellular-fluid drug measurements came from one animal sampled in four brain regions on one dosing occasion. Dopamine measurements came from that same animal on three dosing occasions. Cerebrospinal-fluid samples came from two other animals.

Repeated dosing occasions and multiple probes increase observations, but they do not create additional independent animals. A model supported by these measurements must retain that distinction when its apparent precision is discussed.

Why did the model also use published studies?

The authors needed a wider dose range than the new 0.1 mg/kg experiments provided. They digitized mean concentration or dopamine-response curves from earlier publications. Rat datasets included intravenous and subcutaneous dosing; higher-dose primate data came from rhesus macaques rather than the cynomolgus monkeys used in the new experiments.

Consequently, the analysis combined different rat strains, primate species, routes and sampling schedules. It did not follow one uniform cohort through all doses. Population modeling allowed the investigators to integrate such data, but could not remove every difference between the contributing experiments.

Which assumptions connected plasma exposure with dopamine?

The investigators converted measured total plasma drug concentrations to unbound concentrations using an assumed unbound fraction of 0.6 in both species. Brain distribution parameters were assumed to remain independent of dose over the modeled ranges. Some volumes or clearance terms had to be fixed because the data could not estimate them separately with adequate precision.

The model also assumed that drug-transfer behavior could be applied across brain sampling regions. For the subcutaneous rat dataset lacking corresponding pharmacokinetic measurements, rapid and complete absorption was assumed. These were stated modeling choices, not directly observed facts for every animal and dose.

An estimated brain concentration therefore should be identified as a prediction conditional on those assumptions. It should not be presented as if a probe measured that concentration at every dopamine-response time point.

What did the dopamine time courses add?

The dopamine response did not simply mirror drug exposure throughout the observation period. Time-matched plots showed patterns consistent with acute tolerance, and the final model incorporated delayed negative feedback that limited dopamine input into the extracellular space.

This formulation fit the available data better than the alternative feedback structures tested. It supported a mechanistic account involving both amphetamine’s effects and the system’s response to them. A better fit among candidate models does not prove that every represented molecular step was independently measured or uniquely identified.

Are the model’s tolerance half-lives clinical recovery times?

No. Estimated half-lives governing development and loss of the modeled feedback were 9.6 hours in rats and approximately one hour in nonhuman primates. Those are parameters of a modeled dopamine-response process, not measured durations of intoxication, safe-driving intervals or times to reversal of dependence.

Precision was limited: relative standard errors for the feedback rate constant were 68.1% in rats and 33.9% in primates. Higher-dose primate sampling ended after two hours, substantially shorter than the reported 340-minute plasma elimination half-life following the low dose. The authors said longer sampling and additional higher-dose studies were needed to determine whether the apparent species difference was real.

What does this permit in a forensic evidence review?

The study supports examining how specimen, sampling site, exposure history and feedback assumptions shape an exposure–response model. It does not validate estimating an individual person’s synaptic dopamine concentration, mental state or driving ability from one amphetamine result.

Its strongest contribution is a framework for further experimental testing. The defensible description is an animal model integrating measured and predicted quantities, with translational potential and stated uncertainty. A case-specific human opinion would require evidence beyond the model’s successful fit to these animal datasets.

References

van Gaalen MM, Schlumbohm C, Folgering JH, et al. Development of a semimechanistic pharmacokinetic-pharmacodynamic model describing dextroamphetamine exposure and striatal dopamine response in rats and nonhuman primates following a single dose of dextroamphetamine. Journal of Pharmacology and Experimental Therapeutics. 2019;369(1):107–120. doi:10.1124/jpet.118.254508. Historical primary animal experiments and modeling using additional published data.

A mean central-to-femoral carbamazepine ratio of 0.97 describes similarity between two postmortem sampling sites in four cases. It does not establish that either concentration stayed unchanged from life to death. The distinction matters because the original authors used the findings to support a stronger statement that carbamazepine was not subject to redistribution.

The carbamazepine denominator was four, not 129

Han and colleagues studied 129 selected drug-related cases investigated by South Korea’s National Forensic Service during 2006–2009. The full study reported 76 drugs, with one to six detected in each case. It did not provide 129 paired results for every compound.

Table 3 gave four carbamazepine cases from the investigators’ own dataset. Their average central/peripheral ratio was 0.97, ranging from 0.74 to 1.16. These were ratios of concentrations, not carbamazepine concentrations in mg/L.

The same table contained results from earlier publications, including animal observations. Those entries must not be pooled silently with the four new human cases or counted as additional independent participants in this study.

What did “cardiac blood” mean here?

Femoral blood was collected after the vein was ligated to reduce drawing blood down from central vessels. The specimen labeled cardiac blood was actually collected from the inferior vena cava after opening the chest and abdomen.

The anatomical description should accompany the label. The data should not be retold as four precisely specified heart-chamber samples, nor automatically transferred to an unrecorded blind-stick collection.

Paired specimens were stored in 50 mL plastic tubes at −20°C. The authors reported approximately three hours from arrival at the facility to collection. That was not the death-to-collection interval, which was unavailable for most cases.

What the ratio supported

The values showed relatively limited site differences in these four observations. They provide drug-specific descriptive context for the sampled compartments. The authors interpreted the result as absence of redistribution and suggested central blood could substitute when peripheral blood was unavailable.

However, a ratio near one can occur even if both sites have changed. There was no antemortem specimen in any case, no serial sampling before autopsy, and no known starting concentration against which either site could be compared. The study therefore could not directly measure each person’s change from life to death.

The range also matters: individual values extended below and above one. Reporting only the mean would hide those differences. Four observations cannot establish universal site interchangeability, particularly across untested intervals, decomposition states or collection procedures.

Analytical performance remained relevant

Carbamazepine was among the drugs quantified by GC–MS. Sample preparation and validation drew on earlier reports and laboratory procedures; the paper did not reproduce a complete carbamazepine-specific numerical validation and uncertainty dataset.

The authors expressly noted that quantification variability should be considered when interpreting site ratios. A small numerical departure from one is not automatically a biological effect, while a precise measurement would not solve the missing antemortem comparison.

The paper’s broad redistribution classifications were descriptive judgments, not results of a carbamazepine-specific statistical equivalence test. There was no demonstrated margin within which two specimens could be treated as equivalent for every forensic purpose.

How the finding should be used

Preserve the four-case denominator, actual collection sites, ligation, storage and missing timing evidence. The result can inform interpretation without supplying a correction factor or proving that an autopsy value equals the concentration during life.

It also cannot determine dose, impairment or cause of death on its own. The separate question of ranking redistribution from volume of distribution in the same study has its own limitations; neither a drug-property ranking nor a near-one site ratio replaces a paired time-course experiment.

Primary source

Han E, Kim E, Hong H, Jeong S, Kim J, In S, Chung H, Lee S. Evaluation of postmortem redistribution phenomena for commonly encountered drugs. Forensic Science International. 2012;219:265–271. doi:10.1016/j.forsciint.2012.01.016.

A positive bone finding does not establish that a drug caused death. Despite its overdose-focused title, a 2022 carbamazepine bone study applied its method to a man whose probable death was attributed to chronic ischemic heart disease. The reported bone and blood values demonstrated detection, not a validated bone threshold for poisoning.

What happened in the authentic case?

The report by Fernández-López and colleagues described one 41-year-old man with a postmortem interval of approximately 13 hours. Blood carbamazepine was 3750 ng/mL, which the authors placed within their cited therapeutic blood range. Rib bone was reported at 46 ng/mg.

The blood value is equivalent to 3.75 mg/L. That arithmetic does not make it comparable directly with 46 ng/mg of prepared bone. One describes drug per volume of blood; the other concerns mass-normalized bone analysis after drying and pulverization.

The paper did not identify the blood collection site for this application or provide a paired concentration from before death. It therefore cannot demonstrate how much the man’s blood concentration changed after death.

The title was broader than the observed case

The paper discussed overdose, psychiatric treatment and the possible future use of bone when conventional specimens are unavailable. Those motivations were not the actual outcome established in the one authentic application.

There was no demonstrated carbamazepine overdose cohort, no comparison group of confirmed carbamazepine poisoning deaths, and no exposure-to-death dose series. Describing the man as a proven carbamazepine-overdose death would reverse the reported case context.

Likewise, the approximately 13-hour interval is far removed from a study of years-old skeletal remains. A successful result in this rib specimen did not validate performance after every burial environment or prolonged decomposition process.

What did the bone number mean?

Samples came from the central portions of fifth and sixth ribs. Bone underwent soft-tissue removal, overnight drying at 50°C, pulverization and extraction before GC–MS. The authors used a mass-normalized analyte-to-internal-standard response ratio, reported in concentration units of ng/mg.

The method reported a detection limit below 0.1 ng/mg and a quantitation limit of 0.3 ng/mg, with sertraline as the listed internal standard. Those analytical limits address whether a finding can be detected or numerically reported within the procedure. They do not identify concentrations associated with harmless exposure, impairment or death.

Why one paired observation is not a conversion

The study aimed to improve comparison between bone and blood, but one authentic paired result cannot establish the relationship across people. It provides no distribution of individual ratios, prediction interval, independent validation sample or test of different dosing histories.

Drug incorporation into bone and recovery from a prepared specimen also cannot be assumed to follow the same time course as circulating blood. The study did not experimentally resolve those processes in the man.

Consequently, dividing a new bone result by a quotient constructed from this pair would produce a model-dependent estimate, not a measured blood value. The authors themselves emphasized that bone lacked standardized therapeutic, toxic and lethal reference data.

What a positive bone finding can contribute

The result can support the presence of carbamazepine in the tested material when appropriate identification criteria and quality controls are satisfied. It can complement the history and other available specimens. It cannot independently establish an oral dose, timing of last use, impairment or causal contribution to death.

This is a useful distinction even when the analytical method performs well. Analytical validity and interpretive validity answer different questions: can the substance be measured in this prepared matrix, and what does that measurement establish about the person?

A related blood–bone-marrow methanol experiment involved a different analyte, tissue and species. Its results cannot supply the missing human rib-bone carbamazepine conversion. Preserve those differences rather than treating all skeletal specimens as one interchangeable compartment.

Primary source

Fernández-López L, Mancini R, Rotolo MC, Navarro-Zaragoza J, Hernández del Rincón JP, Falcón M. Carbamazepine Overdose after Psychiatric Conditions: A Case Study for Postmortem Analysis in Human Bone. Toxics. 2022;10:322. doi:10.3390/toxics10060322.

Carbamazepine can be analytically detected in rib bone using a specified extraction and GC–MS procedure. The validation study supporting that conclusion also used mass-normalized response ratios and contained reporting inconsistencies. Its performance data should be evaluated as method evidence, not as proof that a bone concentration directly measures toxicity.

What material was studied?

Fernández-López and colleagues used central portions of the fifth and sixth ribs collected in Murcia, Spain. Specimens were approximately 5 cm long. Three rib specimens from people whose blood was negative for carbamazepine supplied comparison material; this was not a large population of drug-free skeletons.

Surface soft tissue was removed, bone was fragmented, dried overnight at 50°C and pulverized. Powder was kept at −80°C until analysis. A 300 mg portion underwent methanol extraction with ultrasound, followed by solid-phase extraction and GC–MS. Sertraline was listed as the internal standard in the analytical table.

This preparation defines the tested matrix. An intact wet rib, marrow, another bone and dried pulverized rib material should not be assumed to give equivalent results.

How identity was supported

The instrument initially acquired full-scan electron-impact spectra and then used selected-ion monitoring. Table 2 listed carbamazepine retention at 12.9 minutes and ions at m/z 193, 165 and 139. Ion ratios had to remain within 20% of the calibrator averages.

The drug-free pool showed no relevant background after extraction, and no carryover was observed after the highest calibration point. These findings support selectivity under the tested conditions. A retention time near 12 minutes or a single ion alone would not reproduce the complete identification evidence.

What quantitative performance was reported?

Calibration standards were described from the quantitation limit through 500 ng/mg. The determination coefficient was 0.999. The reported detection limit was below 0.1 ng/mg and the quantitation limit was 0.3 ng/mg. Detection and supported numerical quantitation are different claims.

Controls were 10, 150 and 400 ng/mg. Table 3 reported intra-assay relative standard deviations of 1.4%, 2.3% and 0.4%, with inter-assay values of 1.3%, 1.4% and 0.9%. Corresponding absolute errors were 13.6%, 3.3% and 1.9% within assays, and 6.9%, 0.2% and 1.0% between assays.

The prose refers to accuracy results “over 14%,” which conflicts with those table entries. The table values should not be replaced with that inconsistent generalization. The paper also describes a preparation spiked with 50 ng in 0.3 g of bone while other validation quantities use ng/mg. Those descriptions are not interchangeable; the reporting basis needs clarification before reproducing the method from the text alone.

The response-ratio qualification matters

The authors expressed analyte levels through a mass-normalized ratio of analyte peak area to internal-standard peak area, while presenting values in ng/mg. They acknowledged difficulty obtaining recovery information from bone that would provide accurate data. This qualification should remain attached to the numerical results.

Reported extraction recovery was 92.6%, the matrix-effect value 78.8%, and process efficiency 73%. These are different performance measures. None is a biological correction for drug movement after death or a conversion into a blood concentration.

What stability testing covered

The study reported less than 10% concentration change over three freeze–thaw cycles and during its mid-term storage assessment. Methods described monthly triplicate measurements of two samples for six months. These laboratory observations do not validate unchanged drug content during years of burial, environmental exposure or advanced skeletal decomposition.

One authentic positive case demonstrated application, but did not create a population reference interval. The method’s strongest contribution is evidence that a defined bone preparation can produce a supported carbamazepine finding. Questions about poisoning, dose and blood equivalence require additional evidence.

The need to read individual performance results also arises in validation limits within a multianalyte blood assay. A panel or method label cannot replace its actual validation record.

Primary source

Fernández-López L, Mancini R, Rotolo MC, Navarro-Zaragoza J, Hernández del Rincón JP, Falcón M. Carbamazepine Overdose after Psychiatric Conditions: A Case Study for Postmortem Analysis in Human Bone. Toxics. 2022;10:322. doi:10.3390/toxics10060322.

A death investigation can support combined drug toxicity without identifying a unique poisoning lesion at autopsy. That does not mean the interaction between two drugs has been experimentally measured. A reported caffeine–methamphetamine fatality illustrates the difference between a case-based cause-of-death opinion and proof of a specific synergistic mechanism.

The conclusion combined several kinds of evidence

Kim and colleagues reported one 34-year-old man found unresponsive, treated in hospital and pronounced dead approximately six hours later. The history suggested ingestion of caffeine tablets. The investigation ultimately certified combined caffeine and methamphetamine toxicity, with accident as the manner of death.

The conclusion drew on circumstances, medical history, autopsy and toxicology. It was not a controlled comparison of caffeine alone, methamphetamine alone and the combination. There was no untreated comparison group from which to calculate an interaction effect or the probability of survival without one substance.

The autopsy was not simply “normal”

No recent significant injuries were identified. The coronary arteries had no significant atherosclerosis, and the report described most organs as unremarkable. However, the heart weighed 442 g, and the authors discussed cardiomegaly as a possible vulnerability. A patent foramen ovale and a finely granular left kidney were also noted.

Accordingly, “no specific lesion proving poisoning” is more accurate than claiming every anatomical finding was normal. Conversely, the heart weight alone did not demonstrate the terminal rhythm or establish the precise contribution of a cardiac condition.

The report discussed possible arrhythmia and cardiovascular stress. Those proposed pathways were not direct recordings of the terminal physiological mechanism. An integrated attribution to toxicity should not be retold as proof that one particular arrhythmia was observed.

The toxicology came from before death

Caffeine was reported at 180 mg/L, methamphetamine at 0.099 mg/L and lorazepam at 0.023 mg/L in hospital blood collected while the patient was alive. These were not later autopsy concentrations. A positive admission amphetamine test was described separately from the numerical methamphetamine finding.

The paper did not reproduce the detailed screening and confirmation workflow, analytical limits or precision needed to independently reconstruct every laboratory stage. It also did not give the exact blood collection site or a precisely known ingestion-to-sampling interval. Those details should remain unknown rather than be filled in from customary practice.

Reference ranges did not measure the interaction

The authors considered caffeine markedly elevated and stated that methamphetamine alone was not consistent with isolated acute toxicity in this case. Their table and discussion use differing caffeine fatal-reference descriptions: the table lists 13–50 mg/L, while the narrative discusses fatalities above 80 mg/L.

These literature-derived descriptions were not thresholds derived from this single person. Nor did the methamphetamine result become irrelevant because it sat near or below a quoted boundary. Reference intervals do not independently quantify each compound’s contribution in a mixture.

The authors proposed a synergistic stimulant effect. The case did not measure receptor activity, cardiac response under each separate exposure, or an expected additive effect against which synergy could be tested. The proposal is therefore a mechanistic interpretation, not a numerical demonstration of more-than-additive toxicity.

What the case cannot assign

The report cannot apportion a percentage of the death to caffeine versus methamphetamine, establish a universally fatal combination, or determine earlier functional impairment from the measured concentrations. Lorazepam detection likewise does not by itself establish its source, administration timing or causal role.

The useful conclusion is that poisoning assessment requires more than searching for a unique anatomical lesion or comparing one drug with a single table boundary. Preserve the authors’ integrated opinion while distinguishing it from experimental proof of mechanism. For specimen-related context, see the use and limits of hospital specimens in death investigations.

Primary source

Kim DG, Powers S, Gitto L. Death Due to Caffeine and Methamphetamine Toxicity: A Case Report. Cureus. 2024;16(8):e66634. doi:10.7759/cureus.66634.

Blood collected before death avoids postmortem redistribution occurring within the body, but it does not make an ingested-dose calculation exact. In a caffeine fatality report, a hospital-blood concentration of 180 mg/L generated an estimated body burden near 8.8 g. That estimate was not a measured stomach content, a confirmed tablet count or an independently validated reconstruction of the amount swallowed.

Which specimen supplied the number?

Kim and colleagues described a 34-year-old man found unresponsive and transported to hospital. He died approximately six hours later. The report states that the toxicology specimens were collected while he was alive, although critically ill.

The hospital blood contained caffeine at 180 mg/L, methamphetamine at 0.099 mg/L and lorazepam at 0.023 mg/L. These must not be relabeled as postmortem femoral-blood results. The report did not identify a uniform anatomical blood-draw site, an exact collection time relative to ingestion, or a detailed specimen preservation and storage history.

The case paper also did not give numerical assay detection limits, quantitation limits, calibration ranges or precision data for these results. A reported concentration should remain attached to those evidentiary limits rather than acquire an invented validation record.

What the calculation actually estimated

The authors used a distribution volume of 0.7 L/kg and an approximate body weight of 70 kg. Multiplying 0.180 g/L by 0.7 L/kg and 70 kg gives 8.82 g. That is a model-based estimate of the amount distributed in the body under the assumed concentration–distribution relationship.

It is not automatically the oral dose. The calculation does not independently measure absorption, the fraction eliminated before sampling, an individual’s distribution volume, or whether distribution was sufficiently complete for the model to apply. The paper did not experimentally determine those quantities in this patient.

Using antemortem blood removes one important objection: the value was not generated by redistribution within a body after death. It does not resolve the other assumptions or convert the model into a validated inverse-dosing method.

The witness account and numerical estimate were different evidence

The history described approximately eight 200 mg caffeine tablets, equivalent to 1.6 g if that account and tablet strength were complete and correct. Tablets were reportedly present at the scene. At autopsy, gastric contents were grainy, but no intact or fragmented tablets were identified.

The article suggested approximately 40 tablets to account for its estimated body burden. The direct arithmetic using 8.82 g and 0.2 g per tablet gives about 44 tablets, illustrating that even the published count was approximate. Neither count was an observed ingestion history.

The discrepancy should prompt scrutiny of the history and assumptions. It cannot, from this report alone, prove that the witness was wrong, establish precisely how many tablets were consumed, or exclude another caffeine source. Grainy stomach material was not chemically quantified as a recovered caffeine dose.

A concentration and an amount have different units

The paper expresses 180 mg/L also as 180 micrograms/mL; these are numerically equivalent. Neither is an amount in grams until combined with a volume or model. Similarly, the estimated grams in the body are not a measured amount remaining in gastric contents.

Calling the blood result a “lethal dose” would merge a concentration with a dose. The investigators’ cause-of-death assessment integrated the full case and other substances; this calculation did not independently establish causation, impairment or the mechanism of death.

What a case review should preserve

Keep the measured value, specimen timing, assumed distribution volume, weight and calculated estimate in separate steps. Label the output as conditional on the model. A missing postmortem-redistribution problem is useful, but not a substitute for demonstrating every remaining assumption.

Related specimen distinctions arise when hospital blood and serum are recovered for a later death investigation. Recovering an earlier specimen strengthens the record while leaving its original matrix and analytical limitations intact.

Primary source

Kim DG, Powers S, Gitto L. Death Due to Caffeine and Methamphetamine Toxicity: A Case Report. Cureus. 2024;16(8):e66634. doi:10.7759/cureus.66634.

Repeated amphetamine exposure does not produce the same behavioral adaptation under every dosing schedule. A 2018 experiment found reduced locomotor stimulation after repeated oral administration in rats. Its result is useful evidence about that regimen, but the experiment did not directly compare oral dosing with injected dosing or measure later addiction.

The distinction matters because the paper discussed whether a slower, more sustained exposure profile could favor tolerance rather than sensitization. A result consistent with that explanation is different from a study that isolates route of administration as the cause.

What did the investigators administer?

The study used sixty-six male hooded Lister rats, six weeks old at the start. Sixteen received vehicle, sixteen received 2 mg/kg amphetamine, eighteen received 5 mg/kg, and sixteen received 10 mg/kg. The preparation was d-amphetamine sulfate diluted into apple juice and delivered orally by pipette. Vehicle animals received the corresponding water-and-juice preparation.

Animals received treatment on weekdays for four weeks: twenty doses over twenty-eight days, with weekends excluded. Treatment occurred in the holding room rather than repeatedly in the activity-testing chamber. The drug groups were coded, and dose identities were revealed after analyses were completed.

Locomotor activity was recorded on the first and final treatment days, beginning thirty minutes after administration and continuing for one hour. The apparatus counted horizontal light-beam breaks. That outcome describes movement in a chamber, not attention, learning, subjective reward, drug seeking or a clinical treatment response.

What happened after the first dose?

The 5 and 10 mg/kg groups showed greater activity than vehicle and the 2 mg/kg group. The lowest dose did not significantly differ from vehicle on the overall activity comparison. Thus, the starting point was already dose-dependent: the experiment did not establish equivalent initial stimulation at all three doses.

That detail changes the interpretation of later results. Failure to observe sensitization at a dose that did not initially produce a significant overall locomotor increase is not the same result as a demonstrated decline in an initially elevated response.

What changed after repeated treatment?

At 5 and 10 mg/kg, activity was significantly lower on the final treatment day than on the first day. The reported day-comparison p values were 0.005 and 0.007, respectively. These within-group changes supported tolerance to the measured locomotor effect under the tested schedule.

The corresponding overall day comparison was not significant for the 2 mg/kg group, with p=0.551, or for vehicle, with p=0.065. The lower-dose result should therefore be reported as no significant overall change, rather than clear evidence of the same tolerance found at the higher doses.

On the final day, the overall between-dose main effect was not statistically significant, with p=0.083. However, a time-by-dose interaction remained significant. A nonsignificant overall group comparison does not establish equivalence, nor does it mean the minute-by-minute response profiles were identical.

Were the doses proven to reproduce human blood levels?

No plasma amphetamine concentrations were measured in these rats. The investigators selected the lower dose using earlier pharmacokinetic literature and an assumption about linear scaling. They explicitly acknowledged the absence of measured plasma concentrations as a limitation.

Consequently, describing the dosing rationale as an attempt to model clinically relevant exposure is appropriate; describing the rats as having verified therapeutic human blood concentrations is not. An administered mg/kg dose is not a measured ng/mL concentration, and a rat dose cannot be substituted directly for a human prescription dose.

The experiment also did not characterize each animal’s concentration-time profile. An explanation based on a slower rise or more sustained exposure remained informed by prior literature rather than directly established by paired pharmacokinetic measurements in this cohort.

Did oral administration cause tolerance instead of sensitization?

The study established what happened with its oral regimen. It did not include a group receiving injected amphetamine under a matched comparison protocol. The authors compared their result with published injection studies and acknowledged that their own laboratory had not tested that alternative here.

Route, treatment duration, dosing frequency, developmental stage and testing context can all differ between studies. The oral result supports investigating those factors, but cannot separate their individual contributions through a comparison the experiment never performed.

Nor should the result be generalized to every psychostimulant. The authors discussed mixed findings from oral cocaine research and recognized that another drug need not follow the same pattern.

Does less movement establish lower future addiction risk?

The paper proposed that its tolerance finding might help explain relationships between stimulant treatment and later substance use. That was a translational interpretation. The rats were not followed for a human substance use disorder, and the study did not measure later self-administration, compulsive drug taking or response to treatment for addiction.

Reduced locomotor stimulation is therefore not direct evidence of protection against future addiction. The finding also does not establish loss of therapeutic benefit: the experiment did not measure ADHD symptoms or treatment effectiveness.

What is the defensible use of this experiment?

This historical primary study demonstrates locomotor tolerance at the two higher tested oral doses after a specific weekday dosing schedule in male rats. It cautions against assuming that every repeated amphetamine regimen necessarily produces progressively greater movement.

For appraisal of a scientific opinion, the next questions are concrete: was blood exposure measured, was the claimed alternative route actually tested, did the initial response differ by dose, and was the outcome movement or a clinically relevant behavior? Keeping those questions attached to the result preserves its value without converting an animal locomotor finding into a human safety or addiction forecast.

References

Turner AC, Stramek A, Kraev I, Stewart MG, Overton PG, Dommett EJ. Repeated intermittent oral amphetamine administration results in locomotor tolerance not sensitization. Journal of Psychopharmacology. 2018;32(8):949–954. doi:10.1177/0269881118763984. Historical primary research in sixty-six male rats.

Performing a familiar task and learning a new rule are different demands. A 1979 experiment made that distinction unusually clear: the same four pigeons alternated between a stable discrimination task and one whose rules changed between sessions, while investigators examined acute and repeated d-amphetamine exposure.

The study’s enduring value is its experimental question. If a drug’s disruptive effect becomes smaller with repetition, has tolerance developed equally for learning, familiar performance, accuracy and speed? The answer was not uniform across those measurements or across animals.

How did the tasks differ?

Moerschbaecher and colleagues studied four drug-naive Silver King pigeons with prior experience learning conditional discriminations. Drug-naive did not mean task-naive. Animals were maintained at approximately eighty percent of free-feeding body weight, and correct responding earned access to grain.

The birds responded to combinations of colors and shapes. In the performance component, the correct rules remained the same across sessions. In the acquisition component, the combinations requiring particular responses changed from session to session, producing repeated opportunities to learn new discriminations.

The components alternated after ten reinforcements or fifteen minutes, whichever came first. Each session ended after sixty reinforcements. An incorrect response produced a ten-second timeout, after which the same stimulus returned.

This arrangement compared different demands within the same animal and session. It did not make the conditions identical: baseline errors and the frequency of food reinforcement also differed between components.

Which drug exposure and outcomes were measured?

The investigators administered d-amphetamine sulfate or cocaine hydrochloride intramuscularly into the pectoral muscles five minutes before a session. Doses were expressed as the salts. Acute administrations were separated by five days, with baseline and saline sessions between them.

The two central outcomes were percentage errors and running time. Percentage errors used errors divided by correct responses plus errors. Running time excluded time spent in timeout. A longer running time therefore was not simply an arithmetic consequence of including the timeout penalty.

These were controlled animal task measurements. No blood amphetamine concentration, driving outcome or human clinical diagnosis was established by this design.

Was new learning more sensitive to amphetamine?

In three of the four birds, disruption generally appeared at lower doses in the acquisition component than in familiar performance. For one bird, P116, 1.8 mg/kg d-amphetamine increased acquisition errors, while several lower doses increased acquisition running time without affecting familiar performance.

The fourth bird did not follow the predominant pattern in the same way and already showed relatively poor within-session acquisition under control conditions. That exception matters in a study with four subjects: a majority pattern is not a universal response.

Within-session records added information beyond aggregate errors. For P116 at 1.3 mg/kg, total errors did not increase, yet the pattern indicated slower acquisition across the session. An unchanged total error count therefore did not necessarily mean that the learning process was unchanged.

Did repeated exposure normalize every outcome?

With repeated d-amphetamine administration, the initial increases in errors and running time generally became smaller. Where both task components initially showed increased errors, tolerance developed first for familiar performance. In two birds, P117 and P118, acquisition errors and running time did not return to their predrug control ranges.

Another example separated accuracy from speed. For P116 receiving 2.4 mg/kg, acquisition errors returned to the control range relatively rapidly while tolerance to the running-time effect developed more slowly. The dose was subsequently increased to 3.2 mg/kg, producing renewed disruption that again diminished during repeated sessions.

These observations make the endpoint part of the definition. A bird could show less disruption on a familiar discrimination, continued difficulty learning changing rules, or different recovery in errors and running time. Calling the animal simply “tolerant” loses that structure.

What did the cocaine comparisons establish?

The experiment also examined cocaine, but its findings should retain the correct drug labels. After chronic cocaine exposure, d-amphetamine dose-effect curves shifted toward higher doses in two birds, consistent with cross-tolerance for the tested behaviors.

The reverse sequence was less conclusive. After chronic d-amphetamine, the investigators retested only a single high cocaine dose in the other two birds. Familiar-performance errors were reduced, but acquisition errors and running-time effects were unchanged or greater. The authors therefore could not substantiate broad cross-tolerance in that direction from the limited retesting.

Cross-tolerance in selected task outcomes is not a general statement about every action of the two drugs, their concentrations, or their health effects.

Why might reinforcement complicate the explanation?

The acquisition component normally delivered reinforcement less frequently than familiar performance. Drug-induced errors and pauses could change that frequency further. Consequently, differences attributed to learning demands could also involve differences in the consequences of responding.

The authors identified reinforcement frequency as an unresolved influence. The study demonstrated task-dependent effects, but did not isolate one complete mechanism explaining why those effects differed.

What can be carried into an evidence review?

This small, historical animal experiment supports asking precisely which task and outcome showed tolerance. It does not establish an amphetamine dose at which a person can safely drive, learn unfamiliar procedures or perform a skilled occupation.

The practical appraisal question is narrower and useful: did the cited experiment measure familiar performance, acquisition of new behavior, speed, accuracy or all of them—and did every measured outcome actually return to its control range? An opinion about preserved function should identify those distinctions before generalizing from a tolerance finding.

References

Moerschbaecher JM, Boren JJ, Schrot J, Fontes JC. Effects of cocaine and d-amphetamine on the repeated acquisition and performance of conditional discriminations. Journal of the Experimental Analysis of Behavior. 1979;31(1):127–140. doi:10.1901/jeab.1979.31-127. Historical primary research in four pigeons.